Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
Journal: Nature communications
Published: July 12, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: Nature communications
Published: May 10, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: medRxiv : the preprint server for health sciences
Published: December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: Nature communications
Published: January 05, 2023
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.
Journal: Contemporary clinical trials communications
Published: September 29, 2022
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Journal: The breast journal
Published: December 04, 2019
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Journal: The oncologist
Published: November 05, 2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Journal: Journal for immunotherapy of cancer
Published: April 09, 2019
Product review: avelumab, an anti-PD-L1 antibody.
Journal: Human vaccines & immunotherapeutics
Published: November 28, 2018
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Journal: Expert review of vaccines
Published: July 31, 2018
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
Journal: Human vaccines & immunotherapeutics
Published: September 01, 2017
Reduction in Cell Viability and in Homeobox Protein Levels Following in Vitro Exposure to δ-tocopherol in Acute Myeloid Leukemia.
Journal: Nutrition and cancer
Published: March 24, 2016
Last Updated: 09/26/2026